Author
Listed:
- David P. Marciano
(The Scripps Research Institute)
- Dana S. Kuruvilla
(The Scripps Research Institute)
- Siddaraju V. Boregowda
(The Scripps Research Institute)
- Alice Asteian
(The Scripps Research Institute)
- Travis S. Hughes
(The Scripps Research Institute)
- Ruben Garcia-Ordonez
(The Scripps Research Institute)
- Cesar A. Corzo
(The Scripps Research Institute)
- Tanya M. Khan
(The Scripps Research Institute)
- Scott J. Novick
(The Scripps Research Institute)
- HaJeung Park
(The Scripps Research Institute)
- Douglas J. Kojetin
(The Scripps Research Institute)
- Donald G. Phinney
(The Scripps Research Institute)
- John B. Bruning
(School of Molecular and Biomedical Science, The University of Adelaide)
- Theodore M. Kamenecka
(The Scripps Research Institute)
- Patrick R. Griffin
(The Scripps Research Institute)
Abstract
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of insulin sensitizers. Activation of PPARγ by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing to their associated adverse effects on bone. Recently, we reported the development of PPARγ antagonist SR1664, designed to block the obesity-induced phosphorylation of serine 273 (S273) in the absence of classical agonism, to derive insulin-sensitizing efficacy with improved therapeutic index. Here we identify the structural mechanism by which SR1664 actively antagonizes PPARγ, and extend these findings to develop the inverse agonist SR2595. Treatment of isolated bone marrow-derived mesenchymal stem cells with SR2595 promotes induction of osteogenic differentiation. Together these results identify the structural determinants of ligand-mediated PPARγ repression, and suggest a therapeutic approach to promote bone formation.
Suggested Citation
David P. Marciano & Dana S. Kuruvilla & Siddaraju V. Boregowda & Alice Asteian & Travis S. Hughes & Ruben Garcia-Ordonez & Cesar A. Corzo & Tanya M. Khan & Scott J. Novick & HaJeung Park & Douglas J. , 2015.
"Pharmacological repression of PPARγ promotes osteogenesis,"
Nature Communications, Nature, vol. 6(1), pages 1-7, November.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8443
DOI: 10.1038/ncomms8443
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8443. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.